Published on : Apr 19, 2017
Albany, New York, April 19, 2017: The report covers all the important parameters of the Asia Pacific NSCLC market, such as its dynamics, competitive scenario, and geographical segmentation. Lung cancer is the leading cause of cancer-related death worldwide, representing 1.69 million deaths in 2015. Among all types of lung cancer, Non-Small Cell Lung Cancer (NSCLC) is the most common type, accounting for about 85.0% of all the cases. The incidence is likely to increase with the rising number of smokers and expanding base of elderly population. Over 50% of the cases of NSCLC are diagnosed in patients over 65 years of age. As per the finding of the report, the Asia Pacific NSCLC market had a valuation of US$3 bn in 2016 and is poised to rise to US$6.2 bn by the end of 2023, expanding at a CAGR of 10.8% therein.
The poor prognosis, particularly for patients with advanced disease, is creating soaring need for improved therapeutic options. The NSCLC market is, thus, shifting focus from chemotherapy regimens towards targeted therapies for patients with specific biomarkers. Over the coming years, this trend will continue with the development of new targeted therapies to address the high unmet needs of NSCLC patients.
The growing incidence of NSCLC is the primary factor stoking the growth of the Asia Pacific NSCLC market. The rising integration of premium-priced immunotherapies with the first-line NSCLC treatment algorithm is also augmenting the market. However, the limited availability of treatment for patients with squamous cells or other detectable molecular characteristics apart from ALK and EFGR mutations is hampering the growth prospects of the market. Moreover, the patent expiration of several blockbuster therapeutics and the high costs of drugs used in the treatment of NSCLC along with the unfavorable reimbursement scenario are keeping the Asia Pacific market from realizing its utmost potential.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=1049126
While patients with non-squamous histology can be prescribed more efficacious therapies such as Alimta, patients harboring activating mutations in anaplastic lymphoma kinase (ALK) or epidermal growth factor receptor (EGFR) can be treated with targeted therapies, including Iressa, Tarceva, Conmana, Gilotrif, Alecensa, Xalkori, and Zykadia.
Keytruda and Opdivo are monoclonal antibodies (mAbs), which act as immune checkpoint inhibitors targeted towards programmed cell death (PD) 1. These mAbs are relatively recent entrants in the market. The former got a green signal in Japan in 2016 for the first and second-line treatment of patients suffering from PD-L1-positive recurrent/unresectable advanced NSCLC. The latter, on the other hand, gained an approval in Japan in 2015 and in South Korea and Australia in 2016 for the treatment of advanced or metastatic squamous NSCLC.
Other inhibitors in the suit of recent market entrants are Olita and Tagrisso. These EGFR inhibitors are targeted towards EGFR T790M, The former received approval in South Korea in 2016, while the latter was approved by regulatory bodies in Australia, Japan, and South Korea in 2016.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com